Products for Research Use Only

AZ084

CAT: 0804-HY-119217-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-119217-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma[1]. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer[1][2].
CAS Number
929300-19-6
Product Name Alternative
Hydroxypropyl Cellulose, Viscosity(5%):75-150mPa.s, MW 100000, Hydroxypropyl Cellulose, Viscosity(1%):150-400mPa.s, Hydroxypropyl Cellulose, Viscosity(1%):1275-3500mPa.s, Hydroxypropyl Cellulose, Viscosity(1%):4000-6500mPa.s
UNSPSC
12352005
Target
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology; Cancer
Assay Protocol
https://www.medchemexpress.com/az084.html
Purity
99.65
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C1=NC=C(N)C=C1)N2CCC3(CCN(CC4=C5CC(C)(C)OC5=CC=C4)CC3)CC2
Molecular Formula
C26H34N4O2
Molecular Weight
434.57
References & Citations
[1]Connolly S, et al. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration. Biochem Pharmacol. 2012 Mar 15;83 (6) :778-87.|[2]Wang M, et al. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions. Cancer Immunol Immunother. 2022 Apr 15.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CCR8